Metformin Hydrochloride Syri (Metformin Hydrochloride)

Metformin works by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and increasing peripheral insulin sensitivity, primarily through activation of AMP‑activated protein kinase (AMPK). These mechanisms lower circulating glucose without increasing insulin secretion.

The appropriate dose of Metformin Hydrochloride Syri is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Metformin Hydrochloride during pregnancy or lactation should be evaluated by a healthcare provider. While some guidelines allow use when benefits outweigh risks, the decision must be individualized, and patients should discuss potential effects with their clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Metformin is a first‑line biguanide that improves insulin sensitivity without causing weight gain, unlike some sulfonylureas or insulin. It has a well‑established safety profile and cardiovascular benefits, making it a preferred option before adding newer agents such as SGLT2 inhibitors or GLP‑1 receptor agonists.

Metformin Hydrochloride Syri should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Metformin Hydrochloride Syri is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition, especially in patients with renal impairment, hepatic disease, or severe infections. Prompt medical attention is required if symptoms such as unexplained fatigue, muscle pain, or rapid breathing occur.

Metformin should be avoided in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or in those receiving iodinated contrast studies without appropriate renal monitoring.